Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Bristol Myers Squibb & Co (NYSE:BMY) released the first disclosure of results from a prespecified interim analysis of Phase 3 TRANSFORM study of Breyanzi (lisocabtagene maraleucel; liso-cel).
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- Breyanzi cut the risk of disease progression, death, and other events by 65% over the standard of care in patients with second-line relapsed or refractory large B-cell lymphoma (LBCL).
- These data back up results toplined in June, with the study meeting its primary endpoint of demonstrating improvement in event-free survival compared to standard of care, which includes salvage chemo followed by high-dose chemo and an autologous stem cell transplant.
- Patients dosed with Breyanzi posted a median event-free survival of 10.1 months compared with 2.3 months in the SOC arm at a 6.2-month follow-up.
- Meanwhile, Breyanzi posted a median progression-free survival of 14.8 months compared with 5.7 months for SOC.
- Overall survival data weren’t mature at the time of this data cut, but Bristol Myers said the drug had shown a trend favoring efficacy on that front.
- 86% of patients dosed with Breyanzi hit a complete or partial response, with 66% achieving a complete response.
- Meanwhile, 48% of patients on SOC achieved a response, and only 39% saw a complete response.
- During the trial, 50 patients in the SOC transferred to dosing with Breyanzi after failing to respond to three cycles of salvage chemo or seeing their disease progress.
- Price Action: BMY shares closed at $56.36 on Friday.
- Check out our coverage of the American Society of Hematology (ASH) Annual Meeting 2021 here.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.